Compare Mesoblast Limited (MESO) vs Stryker Corporation (SYK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Mesoblast Limited vs Stryker Corporation — how do they compare? Mesoblast Limited trades at $14.29 (market cap $1.75B), while Stryker Corporation trades at $277.33 (market cap $106.24B). The key difference: Stryker Corporation is far larger — about 60.7× Mesoblast Limited's market cap, and Stryker Corporation pays a 1.27% dividend while Mesoblast Limited pays none. Which is the better fit depends on your goals — on Pluang, investors hold Mesoblast Limited for 15 Days and Stryker Corporation for 21 Days on average.
| MESO | SYK | |
|---|---|---|
Market Cap | $1.75B | $106.24B |
Volume | 239,027 | 2,982,001 |
Sector | Health | Health |
52-Week High | $20.96 | $388.35 |
52-Week Low | $13.19 | $269.75 |
Typical Hold Time | 15 Days | 21 Days |
Enterprise Value | $1.83B | $117.70B |
Dividend Yield | — | 1.27% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MESO trades at $13.75, down 1.36% on the day, with a bearish technical signal from moving averages. The company reported a net loss of $102.14 million in 2025, though revenue grew to $120 million in 2026. Recent milestones include FDA approval for a new potency assay and completion of a Phase 3 trial for chronic low back pain, signaling progress in its commercial pipeline.
The outlook is mixed; analyst consensus leans buy (45% buy ratings), but profitability remains a challenge with negative margins. Key risks include high cash burn and competitive pressures, while catalysts hinge on successful commercialization of RYONCIL and upcoming trial results. The stock presents a high-risk, high-reward opportunity in the biotech sector.
Stryker (SYK) trades at $276.97, up 0.57% today, amid a bearish technical signal with key support at $274 and resistance at $279. The company reported strong profitability with a 14.43% net income margin and beat Q2 2026 EPS estimates, though it missed in Q1. Recent news highlights ongoing legal scrutiny related to manufacturing issues disclosed in September 2026, which caused a significant share price drop.
Analyst consensus remains strongly bullish with a $368.11 price target, but risks include persistent manufacturing problems and potential securities litigation. Earnings growth and margin expansion support the long-term outlook, though near-term volatility may persist pending Q3 2026 results on October 29, 2026.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Mesoblast Limited
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →About Stryker Corporation
Stryker is a global leader in medical technology, specializing in Orthopaedics, MedSurg, and Neurotechnology. It is renowned for its highly decentralized business model, which empowers 22 specialized business units to drive innovation and category leadership. With its market-leading Mako SmartRobotics™ platform and a relentless M&A strategy, Stryker provides a comprehensive ecosystem of connected surgical tools, implants, and digital solutions that improve both clinical and financial outcomes for hospitals worldwide.
Read more on SYK →
